A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
Completed · Phase 1 · Has a placebo group
Conditions studied: Schizophrenia
In brief
This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.
Key facts
- Study ID
- NCT04510298
- Run by
- Sirtsei Pharmaceuticals, Inc.
- People needed
- 27
- Starts
- 2020-10-15
- Expected to finish
- 2021-04-15
- Last updated by the study team
- 2022-04-25
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Collaborative Neuroscience Research — Garden Grove, California, United States
- Hassman Research Institute — Marlton, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.